Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL

Jelena Vekic, Aleksandra Zeljkovic, Aleksandra Stefanovic, Natasa Bogavac-Stanojevic, Ioannis Ilias, José Silva-Nunes, Anca Pantea Stoian, Andrej Janez, Manfredi Rizzo

Research output: Contribution to journalReview articlepeer-review

1 Downloads (Pure)

Abstract

Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.

Original languageEnglish
Article number825
JournalPharmaceutics
Volume14
Issue number4
DOIs
Publication statusPublished - 9 Apr 2022

Keywords

  • lipids
  • lipoproteins
  • small dense LDL
  • cholesterol
  • prevention
  • therapy

Fingerprint

Dive into the research topics of 'Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL'. Together they form a unique fingerprint.

Cite this